drugset / Trial / NCT01524380

Ginkgo Biloba Extract for Schizophrenia

NCT01524380

Completed 124 enrolled Beijing HuiLongGuan Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

A double-blind, randomized, placebo-controlled trial of ginkgo biloba extract (Egb-761) as an add-on therapy to risperidone compared to risperidone plus placebo in the treatment of 200 treatment-naive first-episode patients with schizophrenia. The study addresses an immune dysfunction hypothesis of schizophrenia.

Timeline

Start
2011-09
Primary completion
2013-06
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ginkgo Biloba Extract Traditional medicine (herbal / TCM) 400 mg

Indications